CA Patent

CA2135614C — Use of urodilatin in pulmonary and bronchial diseases

Assigned to Haemopep Pharma GmbH · Expires 2009-04-28 · 17y expired

What this patent protects

The present invention relates to the use of a pharmaceutic composition containing urodilatin as an active substance and optionally pharmaceutically usual diluents, excipients, fillers or adjuvants for treating pulmonary and/or bronchial diseases.

USPTO Abstract

The present invention relates to the use of a pharmaceutic composition containing urodilatin as an active substance and optionally pharmaceutically usual diluents, excipients, fillers or adjuvants for treating pulmonary and/or bronchial diseases.

Drugs covered by this patent

Patent Metadata

Patent number
CA2135614C
Jurisdiction
CA
Classification
Expires
2009-04-28
Drug substance claim
No
Drug product claim
No
Assignee
Haemopep Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.